Navigation Links
Arimidex-Herceptin Combo Therapy For Breast Cancer-Clinical Trial Findings

News of interest for post menopausal women with breast cancer positive to hormone receptors and HER2 -addition of both Herceptin (trastuzumab) from Roche// and Arimidex (anastrozole) from AstraZeneca to their treatment improves the length of progression free time by 4.8 months.

A Phase III clinical trial sponsored by Roche showed that Arimidex alone inhibited the progression by just 2.4 months after which the cancer continued to progress.

Hormone sensitive breast cancer is seen in 66% of postmenopausal breast cancer and 25% are HER2 positive. The cancer is therefore a very aggressive form and the chances of relapse are higher.

Roche had already announced in May that the Herceptin-Arimidex combination was proving to be particularly effective. It announced the full findings on Monday in Istanbul at the European Society for Medical Oncology Congress.

Dr. Bella Kaufman, from Israel's Chaim Sheba Medical Centre, who had led the trial, said the findings were extremely positive, as double progression free survival is rare in breast cancer trials.

The trial also showed that overall survival was also prolonged to an average of 28.5 months. However this is not considered statistically significant since patients on Arimidex alone have their survival prolonged to 23.9 months.

Additional data showed that introducing anastrozole instead of Tamoxifen in early hormone sensitive breast cancer among postmenopausal women increased their chances of avoiding disease recurrence.

Source-IANS
'"/>




Page: 1

Related medicine news :

1. Drug Combo Works Better for children with ADHD, Tics
2. Scanning Combo Helps Detect Lung Cancer
3. Relief From Asthma With New Combo Therapy
4. Calcium-Vitamin D Combo For Reduced Fracture Risk
5. Drug Combo Improves Performance Of Multiple Sclerosis Drug
6. Alcohol-illusion: Alcohol and Energy Drinks Combo, Maintains Sobriety?
7. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
8. The Combo Treatment Is Effective to Treat Type 1 Diabetes in Mice
9. Doomed Duo: Obesity and Type 2 Diabetes Combo, Can Nip Life in the Bud
10. Fuzeon and MK-0518 Combo Holds Promise For HIV
11. Germ - Chemo Combo Fights Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – is set to return to the esteemed Quaker Ridge Golf ...
(Date:5/4/2016)... York, NY (PRWEB) , ... May 04, 2016 ... ... leading private owners, developers and operators of commercial real estate proudly announced that ... 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ annual ...
(Date:5/4/2016)... ... May 04, 2016 , ... a2z, Inc. is ... and Canadian Association for Enterostomal Therapy (CAET) will be utilizing powerful and innovative ... to attendees and exhibitors for the 2016 WOCN Society & CAET Joint Conference—which ...
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star ... created to assist the people of their local community. The agency pledges to ... community leaders. Their hope is to bring awareness to important local causes with ...
(Date:5/4/2016)... East Providence, Rhode Island (PRWEB) , ... May ... ... website was launched in April 2016. SS&A teamed up with one of the ... website. This legal information portal contains informative legal articles related to the law ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... Intec Pharma Ltd. (NASDAQ: NTEC ... the appointment of Pnina Strauss-Levy as Vice ... has 15 years of experience in clinical research and ... having supported the advancement of several products through the ... the United States and Europe ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information noted ... Medical Records) market in a recent white paper.  The ... Increased physician usage, a growing market are among the ... in Kalorama,s report EMR 2016: The Market ... Kalorama,s seventh complete study of the EMR industry, and ...
(Date:5/2/2016)... 2016  Celsion Corporation (NASDAQ: CLSN ), ... from the first cohort of patients in its ... Study) combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... In the first three patients dosed, GEN-1 plus ...
Breaking Medicine Technology: